Low serum complement C3 levels are associated with adverse clinical outcomes in myelodysplastic syndromes
Decreased serum complement C3 levels emerge as an independent prognostic biomarker in MDS, correlating with unfavorable clinical outcomes regardless of IPSS-R stratification. This novel parameter offers additional prognostic value and may enhance existing risk assessment tools in the clinical management of MDS.
Authors
- Jie Cao (ORCID: https://orcid.org/0000-0002-8890-0542)
- Huanhuan Ying
- Qitian Mu
- Duobing Zou (ORCID: https://orcid.org/0000-0001-9267-8174)
- Guifang Ouyang (ORCID: https://orcid.org/0000-0002-3411-3666)
- Yanqing Liu (ORCID: https://orcid.org/0000-0003-4033-4016)
- Yong Liang (ORCID: https://orcid.org/0000-0002-1079-7194)
Institutions
- Ningbo University (CN)
Publication Details
- Journal
- Leukemia Research
- Published
- 2025-10-03
- DOI
- https://doi.org/10.1016/j.leukres.2025.108116
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00